-
Mashup Score: 1Neoadjuvant Atezolizumab in Stage IB/IIIB Resectable Lung Cancer - 3 year(s) ago
Neoadjuvant atezolizumab was well-tolerated by patients with stage IB-IIIB lung cancer, according to the primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study. “The LCMC3 study is a unique trial in that it is the largest monotherapy trial of checkpoint inhibition in resectable non-small cell lung cancer (NSCLC),” noted Jay M. Lee, MD, from the UCLA Medical Center, who presented…
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 7AACR 2021: Nivolumab/Chemo Significantly Boosts NSCLC Response - 3 year(s) ago
Nivolumab plus chemotherapy significantly improved pathological complete response rates compared to chemotherapy alone in patients with resectable stage Ib-IIIa non-small cell lung cancer (NSCLC), according to findings presented at the AACR Annual Meeting 2021.
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Lung Cancer Resource Center - 3 year(s) ago
Timely studies, news, quizzes, and resources focusing NSCLC
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Findings from a Phase III study found that evaluating mRNA expression of selected genes to tailor adjuvant chemotherapy did not improve survival outcomes among patients with resected stage II-III non-small cell lung cancer (NSCLC). Final results from the International Tailored Chemotherapy Adjuvant trial (ITACA) were presented at the 2021 International Association for the Study of Lung Cancer…
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Lung Cancer Resource Center - 3 year(s) ago
Timely studies, news, quizzes, and resources focusing NSCLC
Source: know.lww.comCategories: Latest Headlines, OtolaryngologyTweet
-
Mashup Score: 4Sotorasib Shows Durable Response in KRAS p.G12C-Mutated NSCLC - 3 year(s) ago
The Phase II CodeBreaK 100 trial demonstrated the durable clinical benefit and safety of sotorasib for patients with non-small cell lung cancer (NSCLC) who harbor KRAS p.G12C mutations. Study author Bob Li, MD, PhD, MPH, of Memorial Sloan Kettering Cancer Center, presented these findings at the International Association for the Study of Lung Cancer World Conference on Lung Cancer (Abstract…
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5AACR 2021: Nivolumab/Chemo Significantly Boosts NSCLC Response - 3 year(s) ago
Nivolumab plus chemotherapy significantly improved pathological complete response rates compared to chemotherapy alone in patients with resectable stage Ib-IIIa non-small cell lung cancer (NSCLC), according to findings presented at the AACR Annual Meeting 2021.
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
A recent study found that more than 10 percent of lung cancer patients received some treatment in the last 30 days of life, according to data presented at the NCCN 2021 Virtual Annual Conference (Abstract EPR21-040). The researchers noted that this suggests “that a substantial number of patients are still being treated shortly before their death, a practice that warrants further exploration.”
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Cases and Quizzes - 3 year(s) ago
Cases and Quizzes focusing on NSCLC
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Lung Cancer Resource Center - 3 year(s) ago
Timely studies, news, quizzes, and resources focusing NSCLC
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Neoadjuvant Atezolizumab in Stage IB/IIIB Resectable #LungCancer https://t.co/aiQh4FUlgl #cancertreatment #medtwitter via @UCLAHealth https://t.co/ADIRSdajil